BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD.

Beijing Tiantan Biological Products Co., Ltd.

600161

CNE000000WF9

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
28.55 ^CNY	-0.80%		-0.49%	-7.72%

Apr. 12	Tiantan Biological Products' Q1 Profit Jumps 21%; Shares Rise 7%	MT
Apr. 11	Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Beijing Tiantan Biological Products Co., Ltd.(XSSC:600161) added to FTSE All-World Index

September 18, 2023 at 12:00 am EDT

Beijing Tiantan Biological Products Co., Ltd.(XSSC:600161) added to FTSE All-World Index (USD)

Latest news about Beijing Tiantan Biological Products Co., Ltd.

Tiantan Biological Products' Q1 Profit Jumps 21%; Shares Rise 7%	Apr. 12	MT
Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 11	CI
Tiantan Biological Products Scraps Clinical Trial of Intravenous Cytomegalovirus Human Immunoglobulin	Feb. 01	MT
Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Jan. 10	CI
China Baoli Technologies Chairman Redesignated as Vice Chairman	Nov. 29	MT
Didi Global Reports Q3 Revenue of RMB 51.4 Billion, Up 25% YoY	Nov. 13	RE
DIDI- ON NOV 11, YI ZHANG RESIGNED AS DIRECTOR OF THE CO, CHEN S…	Nov. 13	RE
Tiantan Biological Products Secures Another Blood Collection License	Nov. 02	MT
Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
Tiantan Biological Products' Profit Jumps 47.7% in First Three Quarters; Shares Up 5%	23-10-13	MT
Tiantan Biological Products' Unit Gets Nod to Register Intravenous Human Immunoglobulin, Passes Regulatory Inspection	23-09-27	MT
Beijing Tiantan Biological Products Co., Ltd.(XSSC:600161) added to S&P Global BMI Index	23-09-18	CI
Beijing Tiantan Biological Products Co., Ltd.(XSSC:600161) added to FTSE All-World Index	23-09-18	CI
Beijing Tiantan Biological Products Lands Blood Collection License in China’s Liping County	23-09-15	MT
Tiantan Biological Unit Registers Blood Disorder Treatment; Shares Jump 4%	23-09-11	MT
Tiantan Biological Products Secures Another Blood Plasma Collection License	23-09-07	MT
Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-13	CI
Tiantan Biological Products Gets License for Four Plasma Stations	23-06-27	MT
Alibaba Cloud cuts prices by up to 50% for core, storage products	23-04-26	RE
Guangxi Wuzhou Communications' Vice Chairman Resigns	23-04-21	MT
Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-12	CI
Analysis-Alibaba overhaul leaves fate of prized cloud unit up in the air	23-03-31	RE
AgBank Executive Vice President Resigns	23-03-21	MT
Cinda International Rejigs Top Management	23-03-13	MT
Tiantan Biological Products' Blood Station Gets Plasma Collection Permit	23-02-23	MT

Chart Beijing Tiantan Biological Products Co., Ltd.

Duration

Period

Chart Beijing Tiantan Biological Products Co., Ltd.

More charts

BEIJING TIANTAN BIOLOGICAL PRODUCTS CORPORATION LIMITED is a China-based company principally engaged in the biopharmaceutical businesses. The Companyâs primary products include preventive products, blood products and other biological products, such as the influenza A (H1N1) vaccines (split, inactivated),hepatitis B vaccines, poliomyelitis vaccines, measles-mump-rubella (MMR) vaccines, encephalitis B vaccines, influenza vaccinations, bacterial vaccines, human serum albumin (HSA) and intravenous immunoglobulin (IVIG), among others. The Company mainly distributes its products within domestic markets and to Hong Kong markets.

Sector

Pharmaceuticals

Calendar

2024-08-27 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Beijing Tiantan Biological Products Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

28.55 CNY

Average target price

31.86 CNY

Spread / Average Target

+11.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD.	-7.72%	6.49B
CSL LIMITED	-4.06%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+55.83%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+3.75%	8.71B

Biopharmaceuticals